Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023
ABSTRACT This study aims to delineate the epidemiological characteristics and impacts of the Mycoplasma pneumoniae (MP) outbreak, utilizing targeted next-generation sequencing (tNGS) to assess pathogen prevalence and co-infections in pediatric pneumonia cases. Pediatric patients admitted to Wuhan Ch...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-05-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.02463-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722366990483456 |
|---|---|
| author | Changzhen Li Jingjing Rao Xiaomei Wang Lifang Feng Yun Xiang Feng Tang |
| author_facet | Changzhen Li Jingjing Rao Xiaomei Wang Lifang Feng Yun Xiang Feng Tang |
| author_sort | Changzhen Li |
| collection | DOAJ |
| description | ABSTRACT This study aims to delineate the epidemiological characteristics and impacts of the Mycoplasma pneumoniae (MP) outbreak, utilizing targeted next-generation sequencing (tNGS) to assess pathogen prevalence and co-infections in pediatric pneumonia cases. Pediatric patients admitted to Wuhan Children’s Hospital with pneumonia from 1 October 2022 to 31 October 2023 were included. tNGS was used for comprehensive pathogen detection, including MP and other respiratory pathogens, with additional sequencing of the 23S rRNA gene V region to identify macrolide resistance mutations. This study enrolled 10,223 patients with pneumonia with a positivity rate of 98.4% by targeted next-generation sequencing. Fever (86.4%) and cough (79.3%) were the most common symptoms of Mycoplasma pneumoniae pneumonia (MPP). Lung consolidation (25.8%) was a common imaging feature, and corticosteroid use was noted in 22.5% of MPP patients. MP proved to be the primary pathogen, particularly evident during the MP pandemic, which began in March 2023 and peaked in October with a detection rate of 63.2%. Of the 4,397 MPP cases, 34.5% were sole infections, while 65.6% were co-infections, mostly with viruses. The main causative agents of co-infections were Haemophilus influenzae and Rhinovirus. The macrolide resistance rate was 79.03%. The A2063G mutation in the 23S rRNA V region is the dominant mutation. High-sensitivity C-reactive protein and serum amyloid A were significantly elevated in MPP, while the absolute counts of CD3+T, CD4+T, CD8+T, CD19+B, and NK cells were significantly reduced. This study demonstrates the utility of tNGS in identifying MP co-infections and macrolide resistance and highlights the role of inflammatory markers and lymphocyte subpopulations in differentiating MPP from non-Mycoplasma pneumoniae pneumonia for clinical management.IMPORTANCEOur study is of great scientific value as it provides practical solutions to clinical challenges and supports both clinical decision-making and public health policy. First, it presents new and important insights into the application of targeted next-generation sequencing (tNGS) technology, which enables rapid and accurate pathogen detection and overcomes the limitations of conventional diagnostic methods. Second, the large sample size, focusing specifically on children during a Mycoplasma pneumoniae epidemic, provides valuable epidemiologic data specifically for the Wuhan region. Finally, by integrating rapid tNGS detection with inflammatory markers and lymphocyte subsets, our study demonstrates direct clinical applications that have the potential to improve patient outcomes. This approach highlights the practical utility of our research in enhancing clinical decision-making and contributes important knowledge to the field. |
| format | Article |
| id | doaj-art-184fc28e259f4043b24b2a69b8708552 |
| institution | DOAJ |
| issn | 2165-0497 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj-art-184fc28e259f4043b24b2a69b87085522025-08-20T03:11:22ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972025-05-0113510.1128/spectrum.02463-24Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023Changzhen Li0Jingjing Rao1Xiaomei Wang2Lifang Feng3Yun Xiang4Feng Tang5Department of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaDepartment of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaDepartment of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaDepartment of Endocrinology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaDepartment of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaDepartment of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, ChinaABSTRACT This study aims to delineate the epidemiological characteristics and impacts of the Mycoplasma pneumoniae (MP) outbreak, utilizing targeted next-generation sequencing (tNGS) to assess pathogen prevalence and co-infections in pediatric pneumonia cases. Pediatric patients admitted to Wuhan Children’s Hospital with pneumonia from 1 October 2022 to 31 October 2023 were included. tNGS was used for comprehensive pathogen detection, including MP and other respiratory pathogens, with additional sequencing of the 23S rRNA gene V region to identify macrolide resistance mutations. This study enrolled 10,223 patients with pneumonia with a positivity rate of 98.4% by targeted next-generation sequencing. Fever (86.4%) and cough (79.3%) were the most common symptoms of Mycoplasma pneumoniae pneumonia (MPP). Lung consolidation (25.8%) was a common imaging feature, and corticosteroid use was noted in 22.5% of MPP patients. MP proved to be the primary pathogen, particularly evident during the MP pandemic, which began in March 2023 and peaked in October with a detection rate of 63.2%. Of the 4,397 MPP cases, 34.5% were sole infections, while 65.6% were co-infections, mostly with viruses. The main causative agents of co-infections were Haemophilus influenzae and Rhinovirus. The macrolide resistance rate was 79.03%. The A2063G mutation in the 23S rRNA V region is the dominant mutation. High-sensitivity C-reactive protein and serum amyloid A were significantly elevated in MPP, while the absolute counts of CD3+T, CD4+T, CD8+T, CD19+B, and NK cells were significantly reduced. This study demonstrates the utility of tNGS in identifying MP co-infections and macrolide resistance and highlights the role of inflammatory markers and lymphocyte subpopulations in differentiating MPP from non-Mycoplasma pneumoniae pneumonia for clinical management.IMPORTANCEOur study is of great scientific value as it provides practical solutions to clinical challenges and supports both clinical decision-making and public health policy. First, it presents new and important insights into the application of targeted next-generation sequencing (tNGS) technology, which enables rapid and accurate pathogen detection and overcomes the limitations of conventional diagnostic methods. Second, the large sample size, focusing specifically on children during a Mycoplasma pneumoniae epidemic, provides valuable epidemiologic data specifically for the Wuhan region. Finally, by integrating rapid tNGS detection with inflammatory markers and lymphocyte subsets, our study demonstrates direct clinical applications that have the potential to improve patient outcomes. This approach highlights the practical utility of our research in enhancing clinical decision-making and contributes important knowledge to the field.https://journals.asm.org/doi/10.1128/spectrum.02463-24targeted next-generation sequencingMycoplasma pneumoniae pneumonianon-Mycoplasma pneumoniae pneumoniaserum amyloid Alymphocyte subsets |
| spellingShingle | Changzhen Li Jingjing Rao Xiaomei Wang Lifang Feng Yun Xiang Feng Tang Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 Microbiology Spectrum targeted next-generation sequencing Mycoplasma pneumoniae pneumonia non-Mycoplasma pneumoniae pneumonia serum amyloid A lymphocyte subsets |
| title | Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 |
| title_full | Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 |
| title_fullStr | Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 |
| title_full_unstemmed | Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 |
| title_short | Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022–2023 |
| title_sort | navigating the outbreak a comprehensive analysis of pediatric mycoplasma pneumoniae pneumonia via targeted next generation sequencing in wuhan 2022 2023 |
| topic | targeted next-generation sequencing Mycoplasma pneumoniae pneumonia non-Mycoplasma pneumoniae pneumonia serum amyloid A lymphocyte subsets |
| url | https://journals.asm.org/doi/10.1128/spectrum.02463-24 |
| work_keys_str_mv | AT changzhenli navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 AT jingjingrao navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 AT xiaomeiwang navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 AT lifangfeng navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 AT yunxiang navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 AT fengtang navigatingtheoutbreakacomprehensiveanalysisofpediatricmycoplasmapneumoniaepneumoniaviatargetednextgenerationsequencinginwuhan20222023 |